StreetInsider.com News Articles

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing Program is designed to expand access to GeneDx’s industry-leading ExomeDx™ test for patients with suspected Niemann-Pick disease type C, helping clinicians

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Tue, 10 Mar 2026 08:30:00 -0400

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

Zevra Therapeutics, Inc. (ZVRA) PT Raised to $23 at Guggenheim

Tue, 10 Mar 2026 06:42:34 -0400

(Updated - March 10, 2026 6:42 AM EDT)

Guggenheim analyst Eddie Hickman raised the price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA) to $23.00 (from $22.00) while maintaining a Buy rating.

The analyst commented: "Miplyffa's launch continues to perform well, with FY25 results showing a clear acceleration. The recent focus on driving payer coverage and reaching patients outside traditional rare disease centers is proving highly effective, with 24 new prescription enrollment forms (PEFs) added in 4Q alone, bringing the total to 161 since launch. This strong momentum, with many new forms coming from the community setting, reinforces our view that there is

Zevra Therapeutics, Inc. (ZVRA) PT Raised to $23 at Guggenheim

Tue, 10 Mar 2026 06:42:34 -0400

(Updated - March 10, 2026 6:42 AM EDT)

Guggenheim analyst Eddie Hickman raised the price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA) to $23.00 (from $22.00) while maintaining a Buy rating.

Form S-8 ZEVRA THERAPEUTICS, INC.

Mon, 09 Mar 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260309/26132533.html

Form S-8 ZEVRA THERAPEUTICS, INC.

Mon, 09 Mar 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260309/26132533.html

Form 10-K ZEVRA THERAPEUTICS, INC. For: Dec 31

Mon, 09 Mar 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260309/26132462.html

Form 10-K ZEVRA THERAPEUTICS, INC. For: Dec 31

Mon, 09 Mar 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260309/26132462.html

Zevra Therapeutics, Inc. (ZVRA) Tops Q3 EPS by 14c

Mon, 09 Mar 2026 16:14:53 -0400

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q3 EPS of $0.19, $0.14 better than the analyst estimate of $0.05. Revenue for the quarter came in at $34.1 million versus the consensus estimate of $28.05 million.

For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.

Form 8-K ZEVRA THERAPEUTICS, INC. For: Mar 04

Mon, 09 Mar 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260309/26132052.html

Form 8-K ZEVRA THERAPEUTICS, INC. For: Mar 04

Mon, 09 Mar 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260309/26132052.html

Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Thu, 19 Feb 2026 10:38:00 -0400

San Diego, California--(Newsfile Corp. - February 19, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation focuses on Zevra's executive officers and whether investor losses may be recovered under federal securities laws.

What if I purchased Zevra securities?

If you purchased Zevra securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.

Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.

There is no cost or obligation to you.

Background of the investigation

On August 12, 2025, Zevra disclosed

Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Thu, 19 Feb 2026 10:38:00 -0400

What if I purchased Zevra securities?

If you purchased Zevra securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.

Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.

There is no cost or obligation to you.

Background of the investigation

On August 12, 2025, Zevra disclosed